Update on postmenopausal osteoporosis management

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 7, Issue 1, 2007, Pages 48-52

  Clunie, Gavin ^a  

^a IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

Bisphosphonates; Fracture risk assessment; Osteoporosis treatment; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; FOSAVANCE; GLUCOCORTICOID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; STRONTIUM RANELATE; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; BONE DENSITY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG FORMULATION; DYSPEPSIA; ELDERLY CARE; FEMALE; FRAGILITY FRACTURE; HUMAN; INCIDENCE; OSTEOPOROSIS; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK FACTOR; SIDE EFFECT; STEROIDOGENESIS; VITAMIN D DEFICIENCY;

EID: 33847411160     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.7-1-48     Document Type: Review

References (41)

1. van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone 2001;29:517-22.
2. Todd CJ, Freeman CJ, Camilleri-Ferrante C et al. Differences in mortality after fracture of hip: the East Anglian audit. BMJ 1995; 310:904-8.
3. Osnes EK, Lofthus CM, Meyer HE et al. Consequences of hip fracture on activities of daily life and residential needs. Osteoporos Int 2004;15:567-74.
4. Gold DT. The clinical impact of vertebral fractures: quality of life In women with osteoporosis. Review. Bone 1996;18(3 Suppl):S185-9.
5. Torgerson DJ, Iglesias CP, Reid DM. The economics of fracture prevention. In: Barlow DH, Francis RM, Miles A (eds). The effective management of osteoporosis. London: Aesculapius Press, 2001:113-21.
6. Carbonell Sala S, Masi L, Marini F et al. Genetics and pharmacogenetics of osteoporosis. Review. J Endocrinol Invest 2005;28(10Suppl):2-7.
7. Garnero P, Munoz F, Borrel O, Somay-Rendu E, Delmas PD. Vitamin D receptor gene polymorphisms are associated with the risk of fractures in postmenopausal women, independently of bone mineral density. J Clin Endocrinol Metab 2005; 90:4829-35.
8. Delmas PD, van der Langerijt L, Watts NB et al. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res 2005;20:557-63.
9. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
10. Osteoporosis - clinical guidelines: summary and recommendations. London: Royal College of Physicians, 1999. www.rcplondon.ac.uk/files/ osteosummary.pdf
11. Management of osteoporosis (71). Scottish Intercollegiate Guidelines Network, June 2003 (updated April 2004). www.sign.ac.uk/guidelines/ fulltext/71/index.html
12. National Osteoporosis Foundation. www.nof.org/physguide
13. Kanis JA, Johnell O, Oden A et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001;12:989-95.
14. Kanis JA, Borgstrom F, De Laet C et al. Assessment of fracture risk. Review. Osteoporos Int 2005;16:581-9.
15. Abrahamsen B, Vestergaard P, Rud B et al. Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish Osteoporosis Prevention Study. J Bone Miner Res 2006;21:796-800.
16. Siminoski K, Leslie WD, Frame H et al. Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J 2005;56:178-88.
17. McLellan AR, Gallacher SJ, Fraser M, McQuillian C. The fracture liaison service: success of a programme for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 2003;14:1028-34.
18. Parkinson C, Stephenson S, Clunie GP. Endocrine disease in patients with fragility fractures. Osteoporos Rev 2006;14:1-6.
19. National Institute for Health and Clinical Excellence. NICE Technology Appraisal No. 87. London: NICE, 2005.
20. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 21 Falls 31/8/5. London: NICE, 2004.
21. Sanders KM, Nicholson GC, Watts JJ. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 2006;38:694-700.
22. National Institute for Health and Clinical Excellence. NICE Appraisal Consultation Document 30/9/5. London: NICE, 2005. www.nice.org.uk/page.aspx? o=273457
23. Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut 2000;46 (Suppl 1):i1-8.
24. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002;50(Suppl 1):i1-9.
25. Ettinger MP. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Arch Intern Med 2003;163:2237-46.
26. Seeman E, Vellas B, Benhamou C et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006;21:1113-20.
27. Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 2001;29:498-505.
28. Royal College of Physicians. Glucocorticoid-induced osteoporosis. London: RCP, 2002. www.rcplondon.ac.uk/pubs/books/glucocorticoid/index.asp
29. Mosekilde L. Vitamin- D and the elderly. Review. Clin Endocrinol (Oxf) 2005;62:265-81.
30. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-42.
31. LeBoff MS, Kohlmeier L, Hurwitz S et al. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999;281:1505-11.
32. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1 535-41.
33. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risendronate Therapy (VERT) Study Group JAMA 1999;282:1344-52.
34. Chesnut III CH, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9.
35. Miller PD, McCLung MR, Macovei L et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315-22.
36. Solomon DH, Avorn J, Katz JN et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165:2414-9.
37. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.
38. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996;18:517-23.
39. Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.
40. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl Med 2001;344:1434-41.
41. Bone HG, Hosking D, Devogelaer JP et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.